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AbstrAct
The desmosomal cadherin, desmoglein 2 (Dsg2), is deregulated in a variety 
of human cancers including those of the skin. When ectopically expressed in the 
epidermis of transgenic mice, Dsg2 activates multiple mitogenic signaling pathways 
and increases susceptibility to tumorigenesis. However, the molecular mechanism 
responsible for Dsg2-mediated cellular signaling is poorly understood. Here we show 
overexpression as well as co-localization of Dsg2 and EGFR in cutaneous SCCs in 
vivo. Using HaCaT keratinocytes, knockdown of Dsg2 decreases EGFR expression 
and abrogates the activation of EGFR, c-Src and Stat3, but not Erk1/2 or Akt, in 
response to EGF ligand stimulation. To determine whether Dsg2 mediates signaling 
through lipid microdomains, sucrose density fractionation illustrated that Dsg2 is 
recruited to and displaces Cav1, EGFR and c-Src from light density lipid raft fractions. 
STED imaging confirmed that the presence of Dsg2 disperses Cav1 from the cell-
cell borders. Perturbation of lipid rafts with the cholesterol-chelating agent MβCD 
also shifts Cav1, c-Src and EGFR out of the rafts and activates signaling pathways. 
Functionally, overexpression of Dsg2 in human SCC A431 cells enhances EGFR 
activation and increases cell proliferation and migration through a c-Src and EGFR 
dependent manner. In summary, our data suggest that Dsg2 stimulates cell growth 
and migration by positively regulating EGFR level and signaling through a c-Src and 
Cav1-dependent mechanism using lipid rafts as signal modulatory platforms.
INtrODUctION
Desmogleins are transmembrane glycoproteins 
of the adhesion structures desmosomes. Of particular 
interest to this study is desmoglein 2 (Dsg2), which is 
expressed in the basal epidermis, intestinal epithelia, 
cardiac tissue, and hair follicles [1, 2]. The role of Dsg2 
and related desmogleins in desmosome assembly and 
adhesion is well known, but its role beyond cellular 
adhesion is an emerging focus of research. In humans, 
mutations in the Dsg2 gene are the underlying cause of the 
sudden death condition arrhythmogenic right ventricular 
cardiomyopathy [3]; Dsg2 serves as a receptor for 
adenoviruses that are involved in respiratory and urinary 
tract infections [4]; and Dsg2 has been identified as a 
regulator of β-amyloid protein processing in Alzheimer’s 
disease [5]. Ectodomain shedding of Dsg2 disrupts 
intercellular adhesion and promotes cell proliferation to 
promote wound repair in ulcerative colitis [6]. In mice, 
Dsg2 gene knockout results in defects in blastocyst 
proliferation and embryonic lethality [7]. Conversely, 
expression of Dsg2 in the superficial epidermis of 
transgenic mice enhances cell proliferation and increases 
susceptibility to chemical-induced skin carcinogenesis [8]. 
Dsg2 is markedly increased in skin malignancies 
including basal and squamous cell carcinoma (BCC and 
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SCC) [1, 9-12]. Altered Dsg2 expression also occurs in 
prostate and colon cancers, suggesting a role for Dsg2 
in oncogenesis in a variety of epithelial tissues [13-16]. 
Loss of Dsg2 in colonic epithelial carcinoma cells results 
in decreased proliferation and suppresses xenograft tumor 
growth in mice [17]. However, in diffuse-type gastric 
cancers, decreased expression of Dsg2 is associated 
with poor prognosis suggesting that Dsg2 may have 
dual roles as an oncogene and a tumor-suppressor gene 
[18]. The signaling pathways through which Dsg2 exerts 
its observed oncogenic effects remain to be elucidated. 
We previously showed that Dsg2 enhances activation of 
growth and survival pathways, including PI3K/Akt, MEK-
Erk1/2, JAK/Stat3 and NF-κB [8] and alters a number of 
genes important in epithelial dysplasia [19]. Interestingly, 
these signaling pathways are downstream of the epidermal 
growth factor receptor (EGFR) and activation with EGF 
increases association of EGFR binding to Dsg2 [20]. 
Furthermore, Dsg2 upregulates Hedgehog signaling and 
in response to chemical carcinogens, enhances BCC and 
SCC tumor development [21].
The mechanism by which Dsg2 modulates signaling 
may involve its interaction with caveolin-1 (Cav1), an 
integral membrane protein of caveolar lipid rafts [22-
25]. Cav1, through its cytosolic caveolin scaffolding 
domain, can interact with and sequester a number of 
different signaling molecules including EGFR [26]. Both 
tumor growth and anchorage-independent cell survival 
are negatively impacted by Cav1 overexpression [27, 
28]. EGFR-stimulated phosphorylation of tyrosine 14 of 
Cav1 has been shown to promote caveolae formation in 
a c-Src-dependent manner, which in turn promotes EGFR 
sequestration and inactivation [29, 30]. Active signaling 
through EGFR requires disassociation from caveolae; 
given Dsg2’s association with Cav1 and the established 
interactions between Dsg2 and EGFR, we examined the 
potential role of Dsg2-mediated modulation of EGFR 
signaling [14, 17, 22, 31-35].
Herein we report that Dsg2 and EGFR expression 
is upregulated and colocalizes in human SCCs. 
Knockdown of Dsg2 reduces EGFR level and activation. 
Furthermore, Dsg2 mobilizes Cav1, EGFR, and c-Src 
lipid raft localization, altering cell signaling. Additionally, 
overexpression of Dsg2 enhances proliferation and 
migration in cancer cells. Taken together, these results 
reveal a distinct signal-regulating role for Dsg2 beyond its 
function in cell-cell adhesion. 
rEsULts
Dsg2 enhances EGFr level and activation
Dsg2 and EGFR have been shown to enhance 
epithelial cell growth and survival and are overexpressed 
in multiple malignancies, including SCCs. Furthermore, 
we demonstrated that Dsg2 activates the MAPK, PI3K/
Akt and JAK/Stat3 pathways [8]. The mechanism by 
which Dsg2 activates mitogenic signaling is not fully 
determined but has been speculated to be through EGFR. 
To determine whether the interaction between Dsg2 
and EGFR is relevant to skin cancer development, SCC 
tissues were immunostained for Dsg2 and EGFR, showing 
not only upregulation, but also co-localization, of Dsg2 
and EGFR in these tissues in vivo (Figure 1). Next, to 
determine whether Dsg2 modulates EGFR, we generated 
stable HaCaT (spontaneously transformed immortalized 
keratinocyte) cell lines expressing a short hairpin RNA 
(shRNA) directed against human Dsg2 (shDsg2) and 
Green Fluorescent Protein (shGFP) as a negative control. 
Immunofluorescence (Figure 2A) and immunoblotting 
(Figure 2B) show reduced expression of Dsg2 protein in 
HaCaT-shDsg2 knockdown (KD) compared to HaCaT-
shGFP. Quantification of the Western blots demonstrate 
that the shRNA reduced Dsg2 by ~70% and EGFR by 
~40% in HaCaT-shDsg2 as compared to control cells 
(Figure 2B). Collectively, our data demonstrate that 
knockdown of Dsg2 reduced EGFR level in HaCaT cells. 
Changes in Dsg2 did not affect the expression of other 
desmosome-associated proteins in HaCaT cells except 
desmocollin 2 (Dsc2) (Figure 2C). This result contrasts 
colon cancer cells [17], where KD of Dsg2 in malignant 
colonic epithelial cells led to a concomitant increase in 
Dsc2. The mechanism by which Dsg2/Dsc2 modulates 
the expression of each other in keratinocytes likely differs 
from that of simple colon epithelial cells.
Next we sought to determine the effect of Dsg2 on 
EGFR activation. In response to EGF ligand stimulation, 
control HaCaT-shGFP cells showed a robust increase 
in phosphorylated EGFR (P-EGFR, Tyr1173), which 
was dramatically abrogated in Dsg2 KD cells (Figure 
3A). Phosphorylation of EGFR at Tyr1173 is critical for 
downstream MAP kinase signaling [36]. To assess the 
effect of Dsg2 on the MEK/Erk1/2, PI3K/Akt and JAK/
Stat3 signaling pathways, HaCaT-shGFP and -shDsg2 
cells were stimulated with EGF and immunoblotted for 
Phospho-Erk1/2, -Akt, and -Stat3. In response to EGF, 
activation of EGFR resulted in Erk1/2, Akt and Stat3 
phosphorylation (Figure 3B). Reduced expression of Dsg2 
did not affect either Erk1/2 or Akt phosphorylation, but 
dramatically reduced Stat3 phosphorylation (Figure 3B). 
Treatment with the MEK inhibitor PD98059 or the PI3K 
inhibitor Wortmannin blocked Erk1/2 and Akt signaling, 
respectively (Figure 3B). Since EGFR activation is 
upstream of Erk1/2 and Akt, PD98059 and Wortmannin 
did not affect EGFR phosphorylation in response to EGF 
ligand stimulation. Furthermore, Wortmannin had no 
effect on Stat3 phosphorylation while PD98059 treatment 
slightly increased Stat3 activation, likely due to blocking 
the inhibitory Erk1/2-mediated phosphorylation of Stat3 
(Ser727) [37]. 
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In spite of reduced phosphorylation of EGFR at 
tyrosine 1173, Erk1/2 was still activated in response 
to EGF stimulation. To further assess whether Dsg2 
modulates unique EGFR phosphorylation sites, HaCaT-
shGFP and -shDsg2 cells were treated with EGF for 
5 to 60 min, and protein lysates were immunblotted 
for P-EGFR at Tyr1173, Tyr1045 and Tyr845 (Figure 
3C). These phosphorylation sites are associated with 
downstream MAPK activation (Tyr1173), c-Cbl-mediated 
receptor degradation (Tyr1045), and c-Src activation 
(Tyr845) [38-40]. The results showed that Dsg2 KD 
reduced EGFR phosphorylation at Tyr1173 and Tyr845 for 
all time points. Interestingly, phosphorylation at Tyr1045 
was immediate—within 5 min after EGF stimulation—and 
Dsg2 KD only slightly attenuated the signal, suggesting 
that ubiquitin-mediated receptor degradation is largely 
unaffected by loss of Dsg2. These results demonstrate that 
Dsg2 had a distinct role in modulating the phosphorylation 
Figure 1: co-localization of Dsg2 and EGFr in squamous cell carcinomas. Two representative SCCs were co-immunostained 
for Dsg2 (green) and EGFR (red). DAPI to label nuclear DNA (blue). Scale bar = 50 µm.
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of EGFR at Tyr1173 and Tyr845. Furthermore, the MEK/
Erk1/2 pathway was activated either independent of EGFR 
or through a phosphorylation site, different from Tyr1173 
and Tyr845 that was not assessed. 
In addition to HaCaT cells, we also generated A431 
epidermoid cancer cells expressing the shGFP and shDsg2 
Figure 2: Knockdown of Dsg2 reduces EGFr. A. HaCaT keratinocytes were stably transfected with shRNA to GFP (shGFP) 
or Dsg2 (shDsg2) and selected in puromycin. Cells were plated on glass slides and processed for immunofluorescence for Dsg2 (green) 
and EGFR (red). Blue DAPI counterstain for nuclei. Scale bar = 100 µm. b. Total lysates from HaCaT-shGFP and -shDsg2 cells were 
immunoblotted for Dsg2, EGFR and GAPDH for equal loading. Densitometry was performed and histogram bars represent the relative 
amount of Dsg2 normalized GAPDH. Data are expressed as average value ± s.e.m. of at least 3 independent experiments. Dsg2 (shGFP, 
1.00±0.12; shDsg2, 0.25±0.06); EGFR (shGFP, 1.00±0.20; shDsg2, 0.58±0.09); **p < 0.01; ***p < 0.001; t-test. c. HaCaT-shGFP and 
-shDsg2 cells were immunoblotted for Dsg1-4, desmocollin 2 (Dsc2), desmoplakin (DP), plakoglobin (PG), plakophilin 1-3 (PkP1-3), 
E-cadherin (E-cad), β-catenin (β-cat) and GAPDH. Blotting for β-actin and GAPDP showed equal loading. Densitometry represents the 
ratio of Dsc2/GAPDH expressed as average value ± standard of the mean. N = 3. Dsc2 (shGFP, 0.57±0.03; shDsg2, 0.22±0.06); *p < 0.05; 
t-test.
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Figure 3: Dsg2 modulates EGFr and stat3 activation. A. HaCaT-shGFP and -shDsg2 cells were serum-starved and then stimulated 
with EGF (10 nM). Total proteins were immunoblotted for active P-EGFR (Tyr1173), EGFR, and GAPDH as loading control. Densitometry 
was performed, and histogram bars represent the relative amount of Dsg2 and EGFR normalized to GAPDH in untreated cells, and the ratio 
of P-EGFR (Tyr 1173) to total EGFR after 1 hr of stimulation was quantified and plotted. Data are expressed as average value ± s.e.m of at 
least 3 independent experiments. Dsg2 (shGFP, 1.00±0.12; shDsg2, 0.25±0.06); EGFR (shGFP, 1.00±0.20; shDsg2, 0.58±0.09); (shGFP, 
1.00±0.04; shGFP+EGF, 4.39±0.08; shDsg2, 0.22±0.04; shDsg2+EGF, 1.12±0.11); **p < 0.01; ***p < 0.001; t-test. b. HaCaT-shGFP 
and -shDsg2 cells were incubated with PD098059 (50 µM) or Wortmannin (100 nM) for 1 h prior to treatment with EGF (10 nM) for 1 
h. Cell lysate was subjected to Western blotting analysis for P-EGFR (Tyr1173), EGFR, P-Erk (Thr202/Tyr204), P-Akt (Thr308), P-Stat3 
(Tyr705), and GAPDH for loading control. Results shown are representative of three independent experiments. c. HaCaT-shGFP and 
-shDsg2 cells were treated with EGF (10 nM) for 5, 10, 15, 30 and 60 min. Cells were lysed and total proteins immunoblotted for Dsg2, 
EGFR, P-EGFR (Tyr1173, Tyr1045 and Tyr845), and GAPDH as loading control.
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Figure 4: Knockdown of Dsg2 in A431 scc cells reduces EGFr phosphorylation. A. A431 cells were stably transfected with 
shRNA to GFP (shGFP) or Dsg2 (shDsg2) and selected in puromycin. Total cell lysates were immunoblotted for Dsg2, EGFR and P-EGR 
(Tyr1173). Blotting for GAPDH showed equal loading. Densitometry was performed and bars represent the ratio of Dsg2 to GAPDH, total 
EGFR to GAPDH and P-EGFR to total EGFR. Data are expressed as average value ± standard error of the mean of three independent 
experiments. n.s.p > 0.05; *p < 0.05; t-test. b. Immunoblotting of A431-shGFP and -shDsg2 cells for Dsg2 and Dsc2 with GAPDH as loading 
control. .N = 3.
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constructs. A431-shDsg2 cells showed a slight, but not 
statistically significant decrease in total EGFR (Figure 
4A). We attribute this to the substantially high expression 
of endogenous EGFR in A431 cells [41]. Similar to 
previous reports, we observed high levels of activated 
EGFR in control A431 cells [42]. While total EGFR 
was relatively unchanged, P-EGFR was significantly 
reduced in A431-shDsg2 cells suggesting that, similar to 
HaCaT cells, reduced Dsg2 expression suppresses EGFR 
phosphorylation and activation (Figure 4A). Additionally, 
Figure 5: Dsg2 modulates EGFr activation through a c-src-dependent pathway. A. HaCaT-shGFP and -shDsg2 cells were 
stimulated with EGF (10 nM) and proteins immunoblotted for P-c-Src (Tyr416), total c-Src and GAPDH as loading control. Bar graphs 
show relative ratio of total c-Src/GAPDH (left) and P-c-Src (Tyr416)/total c-Src (right). Data are expressed as average value ± s.e.m. 
of three independent experiments. c-Src (shGFP, 1.00±0.16; shDsg2, 1.00±0.30); P-c-Src (shGFP, 1.00±0.08; shGFP+EGF, 0.88±0.15); 
P-c-Src (shDsg2, 0.57±0.16; shDsg2+EGF, 0.40±0.03); Not significant n.s.p > 0.05; *p < 0.05; ***p < 0.001; t-test. b. HaCaT cells were 
treated with the c-Src inhibitor PP2 (30 µM) for 1 h and then stimulated with EGF (10 nM) for 1 h prior to cell lysis. Total cellular proteins 
were subjected to immunoblotting for P-EGFR (Tyr1173), EGFR, P-Stat3 (Tyr705), Stat3, P-c-Src (Tyr416), c-Src and GAPDH. Data are 
expressed as average value ± s.e.m. of six independent experiments. P-EGFR (shGFP, 1.00±0; shGFP+EGF, 5.09±0.49; shGFP+EGF+PP2, 
2.74±0.26); P-c-Src (shGFP, 1.00±0; shGFP+EGF, 1.62±0.22; shGFP+EGF+PP2, 0.67±0.20); P-Stat3 (shGFP, 1.00±0; shGFP+EGF, 
3.74±1.85; shGFP+EGF+PP2, 7.75±1.99); Not significant n.s.p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; t-test.
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similar to the HaCaT-shDsg2 cells, a decrease in Dsc2 
expression was observed in A431-shDsg2 cells, further 
illustrating a lineage-specific modulation of Dsg2/
Dsc2 expression (Figure 4B). Due to the high level of 
endogenous EGFR and P-EGFR in A431 cells, and 
that the A431 cells would rapidly select against loss of 
Dsg2, we chose to use HaCaT cells for further mitogenic 
signaling analysis.
Dsg2 modulates c-src phosphorylation and 
activity
The proto-oncogene c-Src is a known regulator and 
effector of EGFR and Stat3 activation, a transcription 
factor with oncogenic potential and anti-apoptotic 
activities [43-45]. In order to determine whether the 
effect of Dsg2 on EGFR is mediated through c-Src, we 
assessed the levels of total and active phosphorylated 
c-Src. Consistent with previous findings, we observed 
constitutively active P-c-Src (Tyr416) in control HaCaT-
shGFP cells (Figure 5A) [46]. Dsg2 did not affect 
total c-Src; however, activated P-c-Src (Tyr416) was 
dramatically reduced in the Dsg2 KD cells (Figure 
5A). Inhibition of c-Src with the inhibitor PP2 partially 
abrogated phosphorylation of EGFR in response to 
EGF ligand in HaCaT cells (Figure 5B), confirming 
previous findings that c-Src acts both upstream as well 
as downstream of EGFR [47]. Thus, the Dsg2-dependent 
EGFR activation may be modulated, in part, by c-Src. 
Interestingly, inhibition of c-Src slightly increased Stat3 
activation (Figure 5B). Reciprocal regulation of c-Src and 
Stat3 activation has been observed in non-small cell lung 
cancer cell lines (NSCLC) or tumor xenografts treated 
with anti-c-Src modalities and in NSCLC human patients 
[48].
Figure 6: EGFr and c-src signaling is mediated, in part, through lipid rafts. HaCaT-shGFP and -shDsg2 cells were lysed in 
1% TX-100 TNE lysis buffer and proteins separated by ultracentrifugation (38,000 RPM) over a sucrose gradient (5, 35, and 45%). Twelve 
1 mL fractions were collected from the top and prepared for immunoblot analysis using antibodies specific for Dsg2, Cav1, flotillin 1 (Flo1), 
c-Src, EGFR and Actin. Light-density lipid raft fractions: 4 and 5. Bands were quantitated and bar graphs show relative ratio of fractions 
4 and 5 to all fractions. Loss of Dsg2 increases EGFR, c-Src, and Cav1 in the lipid raft fractions. EGFR (shGFP, 1.13±0.21; shDsg2, 
3.17±0.41); c-Src (shGFP, 7.46±2.68; shDsg2, 19.11±3.08); Cav1 (shGFP, 3.17±0.88; shDsg2, 6.70±0.54); *p < 0.05; t-test. 
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Dsg2 alters composition of lipid rafts and activates 
c-src and EGFr
Our previous work identified an interaction between 
Dsg2 and caveolin 1 (Cav1), a known negative regulator 
of the activities of c-Src and EGFR [22, 49, 50]. However, 
it is not known whether Dsg2 modulates EGFR and c-Src 
activity through lipid rafts. Down-regulation of Dsg2 in 
Figure 7: EGFr signaling is mediated through cav1 and lipid rafts. A. HaCaT-shDsg2 and -shGFP cells were treated with 
1% MβCD for 1 h and total protein lysates were immunoblotted for P-EGFR (Tyr1173), EGFR, P-c-Src (Tyr416), c-Src and GAPDH. 
Bar graphs show relative ratio of P-EGFR to total EGFR and P-c-Src to total c-Src. Data are expressed as average value ± s.e.m. of three 
independent experiments. P-EGFR (shGFP, 1.00±0.16; shGFP+MβCD, 2.64±0.12; shDsg2, 0.04±0.01; shDsg2+MβCD, 1.07±0.04); P-c-
Src (shGFP, 1.00±0.20; shGFP+MβCD, 1.10±0.09; shDsg2, 0.17±0.02; shDsg2+MβCD, 0.55±0.04); n.s.p > 0.05; * p < 0.05; t-test. b. 
HaCaT cells were incubated with the biotinylated AP ([(biotin)-RQPKIWFPNRRKPWKK-(OH)]; 5 μM) or the Cav-1 consensus binding 
peptide conjugated to AP (AP-Cav1; [(biotin)-RQPKIWFPNRRKPWKKDGIWKASFTTFTVTKYWFYR-(OH)]; 5 μM) for 1 h prior to 
stimulation with 10 ng/mL EGF for 1 h. Total cell lysates were immunoblotted for P-EGFR (Tyr1173) and GAPDH (for equal loading). Bar 
graph shows quantitated values from 3 independent experiments. 
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HaCaT keratinocytes did not alter total Cav1 level (not 
shown). To determine whether Dsg2 modulates Cav1 
membrane raft localization, we relied on the fact that 
caveolae are buoyant Triton X-100 insoluble membrane 
fractions and can be isolated through sucrose density 
gradient centrifugation [22]. In control cells, we detected 
Cav1, flotillin 1, c-Src and, to a lesser level, EGFR in the 
light density raft fractions 4 and 5 that are demarcated as 
containing constituents of caveolae, per the immunoblot 
for Cav1 (Figure 6). Reduced expression of Dsg2 shifted a 
higher portion of total Cav1, c-Src and EGFR into the raft 
fractions. In contrast, lipid raft localization of flotillin-1, a 
scaffolding protein associated with planar-type lipid rafts, 
was not affected by Dsg2 expression. Cav1 negatively 
regulates cellular signaling by sequestering signaling 
molecules in their inactive state within the caveolae [25]. 
Together these data suggest that Dsg2 enhances activation 
of c-Src and EGFR by disrupting their association with 
lipid rafts. 
Lipid raft-mediated internalization potentially serves 
as a mechanism for EGFR degradation, independent from 
clathrin-dependent endocytosis and membrane recycling. 
Given that lipid rafts can repress extended EGFR 
activation and loss of Dsg2 attenuates receptor activation, 
disruption of either the EGFR-lipid raft or lipid raft-Dsg2 
interactions should promote receptor activation. Methyl-
β-cyclodextrin (MβCD) perturbs lipid raft structure and 
releases its constituents by chelating cholesterol away 
from the rafts. Treatment of HaCaT-shGFP and HaCaT-
shDsg2 cells with MβCD did not alter total level of c-Src 
or EGFR, but increased their activation (Figure 7A). 
Interestingly, KD of Dsg2 decreased the activation of 
P-c-Src and P-EGFR in response to MβCD, corroborating 
with the observed decrease in total EGFR expression in 
HaCaT-shDsg2 cells. To further demonstrate that EGFR 
activation is mediated through Cav1 and caveolae, 
we utilized a fusion of the cell permeable Drosophila 
Antennapedia homeodomain and the Cav1 scaffolding 
domain (Cav1-AP) or a non-specific peptide as a control 
(AP). This Cav1-AP peptide would disrupt the interaction 
between Cav1 and its binding partners including, Dsg2 
and EGFR [20]. In unstimulated HaCaT cells, AP or 
AP-Cav1 peptides did not have an effect on EGFR 
phosphorylation (Figure 7B). EGFR phosphorylation 
increased in response to EGF ligand stimulation and while 
the AP control peptide impaired EGFR phosphorylation, 
AP-Cav1 significantly reduced the phosphorylation level 
(Figure 7B). We previously showed that AP-Cav1, but not 
AP, slightly reduced Dsg2 level in lipid raft fractions [22]. 
Interestingly, AP-Cav1 had no effect on the activation 
of EGFR in HaCaT-shDsg2 cells (not shown), which 
already had abrogated ligand-induced EGFR activation, 
further demonstrating that connection between receptor 
activation and Dsg2. Both MβCD and AP-Cav1 treatment 
in Dsg2-depleted cells illustrate that EGFR activation in 
keratinocytes can be dependent upon the ability of Dsg2 
to modulate receptor association with caveolae. 
To more precisely illustrate that expression of 
Dsg2 disrupts Cav1 membrane localization, we utilized 
stimulated emission depletion (STED) super-resolution 
microscopy [51]. We relied on the fact that the knockdown 
of Dsg2 was not complete in the HaCaT-shDsg2 cells, 
with some patches of HaCaTs expressing Dsg2 and 
permitting the visualization of Cav1 in both the presence 
and absence of Dsg2 (Figure 8A). Confocal images of 
Dsg2 (red), Cav1 (green) and merged demonstrate the 
presence of Dsg2 and Cav1 at cell-cell contacts in both 
Dsg2-expressing and Dsg2-KD HaCaTs (Figure 8A). 
Utilizing STED at an intersection of three cell-cell borders 
for enhanced analysis, Cav1 signal was concentrated 
at the cell-cell border between cells lacking Dsg2 but 
became dispersed and scattered in the presence of Dsg2 
(Figure 8B). This suggests that the physical presence of 
Dsg2 disrupted well-defined Cav1 localization to the cell 
membrane. By calculating the intensity of Dsg2 and Cav1 
staining perpendicularly across both Dsg2-expressing 
and non-expressing cell-cell borders, it was apparent that 
higher Dsg2 expression redistributed Cav1 intracellularly 
(Figure 8B). This disruption of Cav1 by Dsg2 was further 
confirmed by calculating the relative fluorescent intensity 
of Cav1 at cell contacts in Dsg2-overexpressing and 
Dsg2-KD HaCaTs from confocal images (Figure 8C). 
HaCaTs without cell-cell Dsg2 staining had a distinct 
peak of Cav1 centered in and immediately around the cell 
membrane whereas Dsg2-expressing cells generally had 
Cav1 distributed further into the cytosol. These results 
begin to suggest that Dsg2 may promote Cav1/caveolae 
internalization; indeed, the cytosolic shift of Cav1 was 
even apparent in Dsg2-expressing cells that bordered cells 
without Dsg2 (data not shown). We observed modulated 
levels of Cav1 in the perimembrane region, suggesting 
an important dynamic between Dsg2 and membrane-
presentation of Cav1. 
Dsg2 enhances scc cell proliferation and 
migration through EGFr and c-src
To further study the ability of Dsg2 to modulate 
the activation of EGFR and its relevance to cancer, we 
generated stable A431 SCC cells expressing a GFP-
labeled Dsg2 (upper band; Figure 9A). We note that the 
endogenous Dsg2 and the ectopically expressed Dsg2-GFP 
localized similarly in light density fractions confirming 
that Dsg2-GFP did not affect endogenous Dsg2 lipid 
raft association (not shown). We opted to use A431 for 
additional study, as it is a well-characterized keratinocyte-
derived tumorigenic cell line amenable to both Dsg2 
overexpression and phenotypic analysis. Furthermore, 
unlike HaCaTs, A431 cells can be used unstimulated in the 
transwell migration assay. Interestingly, overexpression of 
Dsg2-GFP did not significantly alter the level of EGFR 
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Figure 8: Dsg2 displaces cav1 from cell-cell borders. A. Immunofluorescent staining of HaCaT-shGFP and HaCaT-shDsg2 cells 
for Cav1 (green), Dsg2 (red) and visualized by confocal microscopy showing more defined Cav1 staining in the absence of Dsg2 (arrow). 
b. Staining was visualized and imaged by STED super-resolution microscopy. The average intensity of Cav1 and Dsg2 staining was 
calculated across the cell-cell border of the boxed areas of the merged STED image. Briefly, measurements of the fluorescent intensity for 
both Cav1 and Dsg2 was obtained in ImageJ with a line 6.25 μm long centered on the Cav1 staining (dashed vertical line) and originating 
from left to right (dashed arrow) perpendicularly across the width of the cell-cell border. Multiple line measurements were taken along the 
length of the distinct cell-cell borders and intensity values averaged to produce both the Dsg2-absent (top graph) and Dsg2-positive cell 
border staining of Cav1 and Dsg2. Scale bars = 5 μm. c. Average fluorescent intensity quantitated from Dsg2 (red) and Dsg2 KD (blue) 
cell-cell borders (n = 18 each). *p < 0.05, **p < 0.01***p < 0.001; t-test.
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Figure 9: Dsg2-mediated scc cell growth and migration is dependent on EGFr and c-src. A. A431 cells were transduced 
with retroviruses encoding for GFP-labeled Dsg2. Total protein lysates from A431 and A431-Dsg2/GFP cells were immunoblotted for Dsg2, 
pEGFR, and EGFR. Actin served as loading control. P-EGFR (A431, 100±26.5; A431-Dsg2/GFP, 413±74.5) *p < 0.05; ***p < 0.001; 
t-test. The effect of Dsg2 on cell proliferation and migration was assessed. b. A431 and A431-Dsg2/GFP cells were plated at low density for 
6 days in the presence of Erlotinib, PP2 or both. Cells were trypsinized and counted (n = 14). A431, 100.0±6.6; A431+Erlotinib, 11.9±1.9; 
A431+PP2, 67.4±3.0; A431+Erlobtinib+PP2, 4.1±0.7; A431-Dsg2/GFP, 165.7±16.8; A431-Dsg2/GFP+Erlotinib, 25.4±0.9; A431-Dsg2/
GFP+PP2, 123.4±4.5; A431-Dsg2/GFP+Erlobtinib+PP2, 10.7±0.8. c. For migration, cells treated with Erlotinib, PP2 or both in serum free 
medium were plated in the top chamber and allowed to migrate through an uncoated Transwell membrane in response to serum-containing 
medium in the lower chamber. The membranes were fixed and stained with methylene blue. Cells were counted and presented as percentages 
of the control migration (n = 9). A431, 100.0±7.1; A431+Erlotinib, 53.7±4.6; A431+PP2, 33.1±5.9; A431+Erlotinib+PP2, 20.0±4.9; A431-
Dsg2/GFP, 233.8±37.6; A431-Dsg2/GFP+Erlotinib, 136.7±12.6; A431-Dsg2/GFP+PP2, 159.1±11.3; A431-Dsg2/GFP+Erlotinib+PP2, 
31.9±6.4. 
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but dramatically enhanced endogenous EGFR activation 
(Figure 9A). Using these cell lines, we next sought to 
determine the effect of Dsg2 on cancer cell growth and 
migration and whether it is mediated through EGFR 
and c-Src. Dsg2 enhanced SCC cell growth, which was 
dramatically abrogated in the presence of the EGFR 
Figure 10: Dsg2 enhances fibrosarcoma cell growth and migration. HT1080 cells were transduced with retroviruses encoding 
for GFP-labeled Dsg2. A. Total protein lysates from HaCaT, HT1080 and HT1080-Dsg2/GFP cells were immunoblotted for desmosomal 
proteins and actin as loading control. b. HT1080 and HT1080-Dsg2/GFP cell lysates were immunoblotted for Dsg2 and EGFR showing 
enhanced EGFR level in response to Dsg2. c. Immunofluorescence of HT1080 and HT1080-Dsg2/GFP cells for Dsg2 and Cav1. Nuclei 
stained blue with DAPI. Bar = 100 µm. D. Proliferation was assessed by cell counting. E. Migration potential was assessed by transwell 
migration assay with HT1080 and HT1080-Dsg2/GFP cells. Migrated cells were counted and presented as percentages of the control.
Oncotarget37549www.impactjournals.com/oncotarget
inhibitor Erlotinib (Figure 9B). The c-Src inhibitor PP2 
only slightly reduced cell growth in response to Dsg2, 
suggesting the prevalence of upstream EGFR activation 
as a determinant of growth in these cells. However, the 
combination of EGFR and c-Src inhibitors was synergistic 
in reducing cell proliferation (Figure 9B). In addition to 
modulating growth, Dsg2 also enhanced cell migration 
through a transwell migration assay in response to Fetal 
Bovine Serum (FBS) as a chemotactic factor (Figure 
9C). The Dsg2-mediated increase in migration was 
partially inhibited by Erlotinib and PP2 (Figure 9C) 
further demonstrating the dependence of cell motility and 
invasion upon EGFR and, to an extent, c-Src activation. 
The combination of both inhibitors further abrogated the 
migration of A431-Dsg2/GFP cells. In summary, these 
results demonstrate that Dsg2 plays an active role in 
modulating epithelial cell growth and migration through 
EGFR and c-Src. 
Dsg2 enhances cell growth and migration 
independent of desmosomes
HaCaT and A431 epithelial cells express 
desmosomal proteins and establish desmosomal contacts. 
Desmogleins, including Dsg2, are incorporated into 
these cell-cell junctions, posing a challenge to delineate 
whether the desmosome-bound or desmosome-free Dsg2 
exerted the observed effects on growth and migration. 
To assess the role of Dsg2 independent of desmosomes, 
we employed the HT1080 fibrosarcoma-derived cells. 
These cells express low levels of endogenous Dsg2, but 
no significant amounts of other desmosomal proteins 
(Figure 10A). Stable HT1080 cell lines were established 
expressing Dsg2-GFP; Western blotting analysis 
confirmed expression of the GFP-tagged Dsg2 protein 
(upper band; Figure 10B). Immunofluorescence showed 
both high membrane and cytoplasmic localization of 
Dsg2 (Figure 10C). Furthermore, Dsg2 dramatically 
enhanced EGFR levels (Figures 10B and C). Similar to 
that observed in A431 SCC cells, ectopic overexpression 
of Dsg2 enhanced HT1080 cell proliferation (Figure 
10D) and migration (Figure 10E). These results support 
the non-desmosome role of Dsg2 in cell proliferation and 
migration, possibly through regulating EGFR. 
DIscUssION
In this study we have provided evidence that 
reduced expression of the desmosomal junction protein 
Dsg2 in epithelial keratinocytes reduces the activation 
of both EGFR and c-Src, leading to a reduction in cell 
proliferation. We also have demonstrated that Dsg2 
displaces Cav1, the major integral membrane protein of 
caveolae, as well as c-Src and EGFR, from lipid rafts 
(Figure 6). In a similar manner, disruption of lipid rafts 
with the cholesterol-chelating agent MβCD shifts EGFR 
and c-Src out of lipid raft fractions, resulting in enhanced 
phosphorylation and activation of these two important 
signaling components. Additionally, overexpression of 
Dsg2 potently activates EGFR and enhances proliferation 
and migration tumorigenic A431 and HT1080 cells. Taken 
together, these data suggest a crosstalk between cell 
adhesion and mitogenic signaling and that Dsg2 utilizes 
lipid rafts as a platform to facilitate the activation of 
EGFR and c-Src signaling. 
EGFR phosphorylation at Tyr845 has been shown 
to be c-Src-dependent, which, in turn, activates Stat3 
transcriptional activity [39]. In addition to the role 
of Tyr1173 phosphorylation in downstream MAPK 
activation, SHP-1, a protein tyrosine phosphatase, 
associates with activated EGFR at that residue and 
attenuates receptor-mediated downstream signaling. 
While it is not possible to rule out the effect of Dsg2 
downregulation on other signal transduction pathways 
that alter MAPK pathway activation, decreased EGFR 
Tyr1173 phosphorylation has been shown to interfere with 
the recruitment of SHP-1, but not SHC/Grb2 (mediators 
of EGFR-induced MAPK activation), to active EGFR 
[40]. Without the inhibitory phosphatase activity of SHP-
1, decreased EGFR activation mediated by loss of Dsg2 
may not necessarily lead to significantly decreased MAPK 
signaling. Indeed, the most profound effect observed on 
downstream mitogenic signaling factors as a result of 
decreased receptor activation from Dsg2 knockdown was 
on the c-Src/Stat3 signaling axis.
Cell adhesion proteins are emerging as key players 
in cancer progression and metastasis. We previously 
showed that the desmosomal cadherin Dsg2 is highly 
upregulated in several skin malignancies [9]. Furthermore, 
overexpression of Dsg2 in the epidermis of transgenic 
mice enhances EGFR level and activates mitogenic 
signaling leading to epidermal hyperplasia and sensitivity 
to tumor development [8]. EGFR is overexpressed and/
or activated in many human tumors including SCCs and 
is often correlated to tumor aggressiveness [52]. Indeed, 
we observed consistent co-localization of elevated Dsg2 
and EGFR expression in human SCC samples (Figure 
1) suggesting a functional interaction in the disease. In 
cultured keratinocytes, overexpression of EGFR enhances 
cell proliferation and survival [53, 54]. Overexpression 
of Dsg2 induces potent EGFR expression and activation 
that stimulates cell proliferation and migration (Figures 
9 and 10). This effect is not desmosomal-dependent, as 
the results were recapitulated in the fibrosarcoma-derived 
HT1080 cell line that does not express desmosomes. 
Interestingly, the HT1080 cell line expressed a small 
amount of endogenous Dsg2 that, having been observed 
previously, further suggests a desmosome-independent 
role for Dsg2 [55]. Thus, our finding here that Dsg2 can 
modulate EGFR activation is a critical link that connects 
cell-cell adhesion to mitogenic signaling in skin cancer 
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development. Dsg2 depletion in SK-CO15 colon cancer 
cells also disrupts EGFR signaling [56]. However unlike 
HaCaT keratinocytes, loss of Dsg2 does not alter the total 
level of EGFR in SK-CO15 colon cancer cells. This may 
be due to the constitutively high level of EGFR in cancers 
cells such as A431 or SK-CO15. 
In breast cancer cells, lipid rafts provide a platform 
for the interaction of EGFR and c-Src, leading to activation 
of cellular survival signaling [57]. Here, we observed that 
reduced expression of Dsg2 decreases active P-c-Src, 
which can regulate EGFR activation [43]. We propose 
that by altering Cav1 composition in lipid rafts, Cav1 
has decreased capacity for sequestering and negatively 
regulating signaling complexes within caveolae. Indeed, 
in the presence of Dsg2, the level of c-Src and EGFR is 
similarly reduced in lipid raft fractions.
Upon ligand binding, activated receptor tyrosine 
kinases such as EGFR undergo rapid endocytosis, 
internalization and sorting to lysosomes for degradation 
[58]. It is generally accepted that clathrin-mediated 
endocytosis is the major pathway for internalization of 
EGFR [59, 60]. Mounting evidence, however, supports 
the role of membrane lipid rafts in modulating EGFR 
level and activation. Treatment of HaCaT keratinocytes 
with MβCD leads to accumulation of EGFR in large 
clusters outside of the disrupted rafts resulting in enhanced 
tyrosine kinase activity possibly due receptor clustering 
or loss of inhibition [61]. It has been proposed that 
autoactivation of EGFR may lead to internalization and 
targeting for degradation through lipid rafts. Indeed, the 
absence of Dsg2 has an effect both on the localization 
of EGFR to lipid rafts (Figure 6) and the distribution of 
Cav1 around the membrane (Figure 8); interrogating the 
precise mechanism that Dsg2 influences EGFR trafficking 
through lipid rafts will require additional study. In a 
manner similar to manipulating lipid rafts with cholesterol 
chelating agents, displacement of components from lipid 
rafts results in activation of numerous signaling cascades 
as well as alteration of differentiation markers such as 
involucrin [62]. Transcriptional profiling of keratinocytes 
after treatment with MβCD and identified over 3,000 
differentially regulated genes [63]. It is evident that 
altering lipid raft composition has a significant impact 
on cellular communication and epithelial homeostasis. 
Importantly, our findings provide a potential mechanism 
for keratinocyte morphogenesis and malignant 
transformation by Dsg2.
A number of targeted therapies directed against both 
EGFR and c-Src are approved for the usage in a variety 
of malignancies; no therapies currently exist for Cav1 
[64]. EGFR-targeting small-molecule (gefitinib, erlotinib, 
lapatinib, etc.) and antibody-based (cetuximab and 
panitumumab) treatment modalities have been developed 
to either block ligand-dependent receptor activation 
or cytoplasmic kinase activity. EGFR inhibition-based 
therapies are currently in use for a wide variety of solid 
malignancies including non-small cell lung cancer, breast 
cancer, and prostate cancer [65-67]. Though effective 
in naïve disease, patients often experienced severe 
side effects from the treatments and, depending on the 
malignancy, progress to an EGFR-insensitive disease. 
Additionally, a number of small-molecule tyrosine 
kinase inhibitors (TKI) of c-Src have been shown to 
have significant clinical effect, with the most well 
characterized inhibitor being dasatanib. Dasatanib has 
been used extensively as a second-line therapy in patients 
with chronic myelogenous leukemia with the BCR-ABL 
fusion protein, but, along with other c-Src-targeting TKIs, 
has produced generally disappointing results in solid 
malignancy clinical trials [68]. Combinatorial strategies 
utilizing both EGFR and c-Src-directed inhibitors are 
being explored in various solid tumors. Neither EGFR 
nor c-Src-targeted therapies are approved for usage in 
cutaneous SCCs, though clinical observations and trials 
with cetuximab and gefitinib monotherapy have shown 
efficacy in treating unresectable disease [69-71]. Given 
the overexpression of EGFR and Dsg2 observed in SCCs, 
and the relatively low expression of Dsg2 in the normal 
adult interfollicular epidermis, a combinatorial therapy 
of EGFR inhibitors with a Dsg2-directed modality may 
prove useful in enhancing the effect of EGFR inhibition 
while simultaneous limiting the adverse reactions to the 
treatment [69]. 
Taken together, the data obtained here suggest that 
Dsg2 may play a significant role in tumor development by 
positively regulating EGFR level and signaling through a 
c-Src and Cav1 dependent manner.
MAtErIALs AND MEthODs
Antibodies
Antibodies used were: H145 Dsg2 (1:10,000), Cav1 
(1:40,000), and GAPDH (1:3,000; Santa Cruz, Santa Cruz, 
CA); Actin (1:100,000; Calbiochem, Billerica, MA);; 
Flotillin 1, c-Src, P-c-Src Tyr416, P-c-Src Tyr527, EGFR, 
P-EGFR Tyr1173, P-EGFR Tyr1045, P-EGFR Tyr845, 
P-Erk1/2 (Thr202/Tyr204), P-AKT (Thr308), P-Stat3 
(Tyr705) (1:1,000; Cell Signaling, Danvers, MA); 10D2 
Dsg2 (1:2), 27B2 Dsg1 (1:100), 5H10 Dsg3 (1:100), 
18D4 Dsg4 (1:100), desmocollin-2/3 7G6 (1:10,000), 
20F6 desmoplakin (1:50), 14B11 plakophillin-1 (1:50), 
8H6 plakophillin-2 (1:50), 19A5 plakophillin-3 (1:100), 
11E4 plakoglobin (1:100), 4A2 E-cadherin (1:2,500), 6F9 
β-catenin (1:1,000) [72]; Secondary antibodies: Alexa 
Fluor-488 & -594 (1:400, Molecular Probes, Eugene, OR); 
HRP (1:5,000; Jackson Labs, Bar Harbor, ME); IRDye 
680 & 800(1:20,000; LI-COR Biosciences, Lincoln, NE); 
Secondary antibodies for STED-imaging: Mega520-
conjugated anti-Rabbit (Sigma-Aldrich) and Star635P-
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conjugated anti-Mouse (Abberior GmbH, Göttingen, 
Germany).
Molecular constructs
Short hairpin RNAs (shRNA) targeting human Dsg2 
were generated by the synthesis of oligonucleotides per the 
pSuper retro puro user manual (Oligoengine, Seattle, WA) 
using the gene specific sequences: (‘5-GAT CCC CGA 
GAG GAT CTG TCC AAG AAT TCA AGA GAT TCT 
TGG ACA GAT CCT CTC TTT TT-3’ and ‘5-AGC TTA 
AAA AGA GAG GAT CTG TCC AAG AAT CTC TTG 
AAT TCT TGG ACA GAT CCT CTC GGG-3’). Control 
shRNA targeting Green Fluorescent Protein was generated 
as previously described [73]. Oligos were annealed and 
ligated to pSuper-retro-puro. Retroviral particles were 
generated and stable HaCaT (immortal keratinocytes) 
and A431 (squamous carcinoma) cell lines were selected 
in medium containing 2 μg/mL puromycin. The Dsg2 
cDNA was subcloned upstream of GFP in pEGFP-N1 
(Clontech, Mountainview, CA). The GFP and Dsg2-GFP 
cDNAs were subcloned into the retroviral expression 
vector LZRS-ms-neo and transfected into Phoenix cells. 
Retroviral particles were generated and stable A431 and 
HT1080 (fibrosarcoma) cells were selected in G418 (50 
μg/ml) as previously described [73]. During the course 
of this study we made several interesting observations. 
First, it was difficult to maintain the Dsg2 knock-down 
phenotype in A431 SCC cells as the cultures would select 
for Dsg2-expressing cells over time, even in the presence 
of selection medium. Second, the Dsg2-GFP construct 
used to overexpress Dsg2 in the A431s did not adequately 
overexpress the protein in HaCaTs. These cells would 
often slightly downregulate endogenous Dsg2 and have a 
similar level of total Dsg2 to that of the control cells.
cell culture and drug treatment
HaCaT, A431, and HT1080 cells were maintained 
in DMEM complete medium containing 10% fetal bovine 
serum (FBS; Fisher, Waltham, MA) and 1X penicillin/
streptomycin (Fisher) as previously described [74, 75]. 
Cells were incubated in serum-free DMEM for 1 h prior to 
treatment with EGF (10 ng/mL; Invitrogen, Carlsbad, CA) 
for the indicated time (0-60 min). In some experiments, 
cells were pre treated with PD098059 (50 µM; BioMol 
Research, Plymouth Meeting, PA), Wortmannin (100 
nM; BioMol Research), or PP2 (10 µM; Millipore Corp., 
Billerica, MA) for 1 h. prior to EGF stimulation. To disrupt 
lipid rafts, cells were treated with MβCD (1 %) for 1 h.
Proliferation assay
Cellular proliferation rate was determined by 
counting the number of cells after 6 days of proliferation. 
Cells were seeded in triplicate at 5x103 cells per chamber 
of 12-well culture plates (Corning, Corning, NY) in 
complete DMEM with DMSO, Erlotinib (1μM), PP2 
(5μM) or the combination treatment. Six days post 
seeding, cells were trypsinized (0.25% Trypsin-EDTA) 
and counted. 
transwell migration assay
Cell migration was performed with 5x103 HT1080 
cells or 5x104 A431 cells plated in the top chamber of the 
Transwell insert on an uncoated membrane (8 μm pores 
for A431 and 2 μm pores for HT1080; Corning). Cells 
were seeded in the upper chamber in serum-free DMEM 
with the same concentration of inhibitors utilized for the 
proliferation assay; 10% FBS-containing DMEM was 
the chemoattractant in the lower chamber. Cells were 
allowed to migrate for 18-24 h then rinsed in PBS,fixed 
in paraformaldehyde and stained with 0.5% crystal violet 
in 50% methanol. Unmigrated cells in the upper chambers 
were removed with a cotton swab, and migrated cells in 
the lower chambers were imaged in 5 random fields using 
an inverted microscope (EVOS, Life Technologies, Grand 
Island, NY). 
Isolation of lipid raft fractions
Cells were lysed with TNE buffer (25 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA) containing 
1% TX-100 and supplemented with PMSF (1 mM), 
protease inhibitors (Roche Diagnostics, Indianapolis, 
IN), and phosphatase inhibitors (Sigma, St. Louis, MO) 
and homogenized with a Dounce Homogenizer. Equal 
volume of 90% sucrose and cell lysate were mixed and 
overlayed with equal volume of 35% sucrose followed by 
5% sucrose all in TNE buffer. Samples were centrifuged 
at 4°C for 18-20 h at 38,000 rpm using an SW41Ti rotor 
(Beckman Coulter, Brea, CA). From top, twelve fractions 
were collected and prepared for Western blotting analysis. 
cell immunoblotting and immunohistochemistry
Cells were lysed with lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% TX-
100) supplemented with PMSF, protease and phosphatase 
inhibitors and heated to 95°C for 10 m in Laemmli 
buffer. Proteins were resolved over SDS-PAGE gel (Bio-
Rad Labs, Hercules, CA). Membranes were blocked in 
Odyssey blocking buffer (LI-COR, Lincohn, NE) and 
incubated in primary antibody overnight at 4°C, followed 
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by secondary antibody. Infrared bands were visualized by 
LI-COR Odyssey imaging system. For immunostaining, 
cultured cells were fixed in 1% paraformaldehyde and 
permeabilized with 1% TX-100 in PBS. Immunostaining 
on formalin-fixed paraffin embedded sections was 
performed as previously described [8]. 
stimulated emission depletion microscopy (stED)
After immunostaining, cells were mounted in 
Mowiol-DABCO (Sigma) and imaged with a Leica TCS 
STED (SP5) confocal microscope (Buffalo Grove, IL, 
USA). Mega520 and Star635P were excited at 531 nm and 
635 nm respectively using pulsed diode lasers (PicoQuant, 
Berlin, Germany). Fluorescent molecules were depleted 
at 765 nm with a tunable titanium-sapphire laser (MaiTai 
HP, Spectra- Physics, Santa Clara, CA) and emission 
was detected with an avalanche photodiode detector 
(Perkin Elmer, Waltham, MA) at 665-705 nm range. 
To avoid overlap between the Mega520 and Star635P 
channels, image acquisitions were sequentially conducted 
at 531 then 635 nm (Laboratory of Biophysics, Institute 
of Biomedicine and MediCity Research Laboratories, 
University of Turku, Finland).
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